Research ExplorerPublicationsManagement of accidental exposure to Ebola virus in the bios...

Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.

Standard

Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. / Günther, Stephan; Feldmann, Heinz; Geisbert, Thomas W; Hensley, Lisa E; Rollin, Pierre E; Nichol, Stuart T; Ströher, Ute; Artsob, Harvey; Peters, Clarence J; Ksiazek, Thomas G; Becker, Stephan; Jan, Ter Meulen; Olschläger, Stephan; Schmidt-Chanasit, Jonas; Sudeck, Hinrich; Burchard, Gerd-Dieter; Schmiedel, Stefan.

In: J INFECT DIS, Vol. 204 Suppl 3, 2011, p. 785-790.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Günther, S, Feldmann, H, Geisbert, TW, Hensley, LE, Rollin, PE, Nichol, ST, Ströher, U, Artsob, H, Peters, CJ, Ksiazek, TG, Becker, S, Jan, TM, Olschläger, S, Schmidt-Chanasit, J, Sudeck, H, Burchard, G-D & Schmiedel, S 2011, 'Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.', J INFECT DIS, vol. 204 Suppl 3, pp. 785-790. <http://www.ncbi.nlm.nih.gov/pubmed/21987751?dopt=Citation>

APA

Günther, S., Feldmann, H., Geisbert, T. W., Hensley, L. E., Rollin, P. E., Nichol, S. T., Ströher, U., Artsob, H., Peters, C. J., Ksiazek, T. G., Becker, S., Jan, T. M., Olschläger, S., Schmidt-Chanasit, J., Sudeck, H., Burchard, G-D., & Schmiedel, S. (2011). Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J INFECT DIS, 204 Suppl 3, 785-790. http://www.ncbi.nlm.nih.gov/pubmed/21987751?dopt=Citation

Vancouver

Günther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J INFECT DIS. 2011;204 Suppl 3:785-790.

Bibtex

@article{24ff013b52d4402db1c95c357e13b086,
title = "Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.",
abstract = "A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10(7) plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.",
keywords = "Animals, Germany, Humans, Mice, RNA, Viral/blood, Containment of Biohazards, *Ebola Vaccines/administration & dosage/standards, *Ebolavirus, Hemorrhagic Fever, Ebola/*prevention & control, Laboratory Infection/*prevention & control, *Needlestick Injuries/virology, Occupational Exposure, Post-Exposure Prophylaxis/*methods, Research Personnel, Vaccines, Attenuated, Vaccines, DNA/immunology, Vesiculovirus/genetics, Viremia, Animals, Germany, Humans, Mice, RNA, Viral/blood, Containment of Biohazards, *Ebola Vaccines/administration & dosage/standards, *Ebolavirus, Hemorrhagic Fever, Ebola/*prevention & control, Laboratory Infection/*prevention & control, *Needlestick Injuries/virology, Occupational Exposure, Post-Exposure Prophylaxis/*methods, Research Personnel, Vaccines, Attenuated, Vaccines, DNA/immunology, Vesiculovirus/genetics, Viremia",
author = "Stephan G{\"u}nther and Heinz Feldmann and Geisbert, {Thomas W} and Hensley, {Lisa E} and Rollin, {Pierre E} and Nichol, {Stuart T} and Ute Str{\"o}her and Harvey Artsob and Peters, {Clarence J} and Ksiazek, {Thomas G} and Stephan Becker and Jan, {Ter Meulen} and Stephan Olschl{\"a}ger and Jonas Schmidt-Chanasit and Hinrich Sudeck and Gerd-Dieter Burchard and Stefan Schmiedel",
year = "2011",
language = "English",
volume = "204 Suppl 3",
pages = "785--790",
journal = "J INFECT DIS",
issn = "0022-1899",
publisher = "Oxford University Press",

}

RIS

TY - JOUR

T1 - Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.

AU - Günther, Stephan

AU - Feldmann, Heinz

AU - Geisbert, Thomas W

AU - Hensley, Lisa E

AU - Rollin, Pierre E

AU - Nichol, Stuart T

AU - Ströher, Ute

AU - Artsob, Harvey

AU - Peters, Clarence J

AU - Ksiazek, Thomas G

AU - Becker, Stephan

AU - Jan, Ter Meulen

AU - Olschläger, Stephan

AU - Schmidt-Chanasit, Jonas

AU - Sudeck, Hinrich

AU - Burchard, Gerd-Dieter

AU - Schmiedel, Stefan

PY - 2011

Y1 - 2011

N2 - A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10(7) plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.

AB - A needlestick injury occurred during an animal experiment in the biosafety level 4 laboratory in Hamburg, Germany, in March 2009. The syringe contained Zaire ebolavirus (ZEBOV) mixed with Freund's adjuvant. Neither an approved treatment nor a postexposure prophylaxis (PEP) exists for Ebola hemorrhagic fever. Following a risk-benefit assessment, it was recommended the exposed person take an experimental vaccine that had shown PEP efficacy in ZEBOV-infected nonhuman primates (NHPs) [12]. The vaccine, which had not been used previously in humans, was a live-attenuated recombinant vesicular stomatitis virus (recVSV) expressing the glycoprotein of ZEBOV. A single dose of 5 × 10(7) plaque-forming units was injected 48 hours after the accident. The vaccinee developed fever 12 hours later and recVSV viremia was detectable by polymerase chain reaction (PCR) for 2 days. Otherwise, the person remained healthy, and ZEBOV RNA, except for the glycoprotein gene expressed in the vaccine, was never detected in serum and peripheral blood mononuclear cells during the 3-week observation period.

KW - Animals

KW - Germany

KW - Humans

KW - Mice

KW - RNA, Viral/blood

KW - Containment of Biohazards

KW - Ebola Vaccines/administration & dosage/standards

KW - Ebolavirus

KW - Hemorrhagic Fever, Ebola/prevention & control

KW - Laboratory Infection/prevention & control

KW - Needlestick Injuries/virology

KW - Occupational Exposure

KW - Post-Exposure Prophylaxis/methods

KW - Research Personnel

KW - Vaccines, Attenuated

KW - Vaccines, DNA/immunology

KW - Vesiculovirus/genetics

KW - Viremia

KW - Animals

KW - Germany

KW - Humans

KW - Mice

KW - RNA, Viral/blood

KW - Containment of Biohazards

KW - Ebola Vaccines/administration & dosage/standards

KW - Ebolavirus

KW - Hemorrhagic Fever, Ebola/prevention & control

KW - Laboratory Infection/prevention & control

KW - Needlestick Injuries/virology

KW - Occupational Exposure

KW - Post-Exposure Prophylaxis/methods

KW - Research Personnel

KW - Vaccines, Attenuated

KW - Vaccines, DNA/immunology

KW - Vesiculovirus/genetics

KW - Viremia

M3 - SCORING: Journal article

VL - 204 Suppl 3

SP - 785

EP - 790

JO - J INFECT DIS

JF - J INFECT DIS

SN - 0022-1899

ER -